๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Glioma
Clinical trial register · United States · industry-sponsored

Glioma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9126 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 26 Sep 2026, 03:16 UTC
9126
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 8 Florida 7 New York 6 Illinois 4 Michigan 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Glioma trials in the USA

14 of 9126 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT07703436Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, New Jersey, New York, Ohio
2027-03
Not yet open
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
NCT07781852Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
Lumina Pharmaceuticals Inc
Phase EARLY_PHASE1
40
Massachusetts, Michigan, New York
2026-09-01
Recruiting
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
NCT07464925Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
Tetragon Biosciences Ltd
Phase 1
30
Florida, Illinois, New York
2026-04-20
Recruiting
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07486713AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
Rigel Pharmaceuticals
Phase 4
16
California, New York
2026-02-23
Active, closed
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706Glioma
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Recruiting
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
NCT05916313Glioma
Boehringer Ingelheim
Phase 1
20
California, Tennessee
2024-01-30
Recruiting
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
NCT06011109Glioma, Glioblastoma Multiforme
Aveta Biomics, Inc.
Phase 1/2
30
Minnesota, Nebraska
2023-12-13
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
Nuvation Bio Inc.
Phase 3
365
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-06-05
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
Jazz Pharmaceuticals
Phase 3
510
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-01-23
Active, closed
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
Pfizer
Phase 1
148
Alabama, Arkansas, California, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2022-11-30
Active, closed
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
Pfizer
Phase 1
103
Arkansas, Colorado, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio
2022-07-05
Active, closed
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
NCT04521686Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Eli Lilly and Company
Phase 1
200
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2020-10-01
Recruiting
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
NCT01906385Glioma
Cerenome
Phase 1/2
55
New York, Texas
2015-06-03
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/glioma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,126 studies in total at the last sync on 26 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Glioma.

How many Glioma trials are recruiting in the US?

8 of the 14 studies on this page are recruiting new participants as of the 26 Sep 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Glioma), 14 studies
PhaseStudiesRecruitingShare
Phase 16342.9%
Phase 1/22214.3%
Phase 22014.3%
Phase 32214.3%
Phase 4117.1%
Phase EARLY_PHASE1107.1%

Most active sponsors

Lead sponsors with the most studies (Glioma)
Lead sponsorStudiesRecruiting
Cerenome22
Eli Lilly and Company20
Nuvation Bio Inc.21
Pfizer20
Aveta Biomics, Inc.11
Boehringer Ingelheim11
Jazz Pharmaceuticals11
Lumina Pharmaceuticals Inc10
Rigel Pharmaceuticals11
Tetragon Biosciences Ltd11

Top states

Top states (Glioma), by number of studies with a site there
StateStudies
California8
Florida7
New York6
Illinois4
Massachusetts4
Michigan4
Arizona3
Connecticut3
Indiana3
Minnesota3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.